|
🐜
|
Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues
20 auth.
F. van Bömmel,
R. D. de Man,
H. Wedemeyer,
K. Deterding,
J. Petersen,
P. Buggisch,
A. Erhardt,
D. Hüppe,
K. Stein,
J. Trojan,
...
C. Sarrazin,
W. Böcher,
U. Spengler,
H. Wasmuth,
Jurrien G.P. Reinders,
B. Möller,
P. Rhode,
H. Feucht,
B. Wiedenmann,
T. Berg
|
8 |
2010 |
8
🐜
|
|
🐜
|
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
29 auth.
J. Wrangle,
V. Velcheti,
M. Patel,
E. Garrett-Mayer,
E. Hill,
J. Ravenel,
Jeffrey S. Miller,
M. Farhad,
Kate Anderton,
Kathryn G Lindsey,
M. Taffaro-Neskey,
C. Sherman,
Samantha Suriano,
M. Swiderska-syn,
Amy M Sion,
...
J. Harris,
Andie R Edwards,
J. Rytlewski,
C. Sanders,
E. Yusko,
M. Robinson,
C. Krieg,
William L. Redmond,
J. Egan,
P. Rhode,
Emily K. Jeng,
A. Rock,
H. Wong,
M. Rubinstein
|
8 |
2018 |
8
🐜
|
|
🐜
|
IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.
12 auth.
Kai-ping Han,
Xiao-yun Zhu,
Bai Liu,
Emily K. Jeng,
Lin Kong,
J. Yovandich,
...
V. Vyas,
W. Marcus,
P. Chavaillaz,
Christian A Romero,
P. Rhode,
H. Wong
|
7 |
2011 |
7
🐜
|
|
🦁
|
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
19 auth.
P. Rhode,
J. Egan,
Wenxin Xu,
H. Hong,
G. Webb,
Xiaoyue Chen,
Bai Liu,
Xiao-yun Zhu,
J. Wen,
Lijing You,
...
Lin Kong,
A. Edwards,
Kai-ping Han,
Sixiang Shi,
Sarah Alter,
J. Sacha,
Emily K. Jeng,
W. Cai,
H. Wong
|
7 |
2015 |
7
🦁
|
|
🐜
|
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.
13 auth.
Wenxin Xu,
Monica Jones,
Bai Liu,
Xiao-yun Zhu,
C. B. Johnson,
A. Edwards,
Lin Kong,
Emily K. Jeng,
Kai-ping Han,
W. Marcus,
...
M. Rubinstein,
P. Rhode,
H. Wong
|
7 |
2013 |
7
🐜
|
|
🐜
|
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
17 auth.
K. Margolin,
C. Morishima,
V. Velcheti,
Jeffrey S. Miller,
Sylvia M. Lee,
A. Silk,
S. Holtan,
Andreanne Lacroix,
S. Fling,
J. Kaiser,
...
J. Egan,
Monica Jones,
P. Rhode,
A. Rock,
M. Cheever,
H. Wong,
M. Ernstoff
|
7 |
2018 |
7
🐜
|
|
🐜
|
Novel Human Interleukin-15 Agonists
9 auth.
Xiao-yun Zhu,
W. Marcus,
Wenxin Xu,
Hyung-il Lee,
Kai-ping Han,
J. Egan,
...
J. Yovandich,
P. Rhode,
H. Wong
|
7 |
2009 |
7
🐜
|
|
🐜
|
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
21 auth.
M. Rosario,
Bai Liu,
Lin Kong,
Lynne I Collins,
Stephanie E. Schneider,
Xiaoyue Chen,
Kai-ping Han,
Emily K. Jeng,
P. Rhode,
Jeffrey W. Leong,
...
Timothy Schappe,
B. Jewell,
Catherine R. Keppel,
Keval Shah,
B. Hess,
R. Romee,
D. Piwnica-Worms,
A. Cashen,
N. Bartlett,
H. Wong,
T. Fehniger
|
7 |
2015 |
7
🐜
|
|
🐜
|
Therapeutic administration of IL‐15 superagonist complex ALT‐803 leads to long‐term survival and durable antitumor immune response in a murine glioblastoma model
9 auth.
D. Mathios,
Chul-Kee Park,
W. Marcus,
Sarah Alter,
P. Rhode,
Emily K. Jeng,
...
H. Wong,
D. Pardoll,
M. Lim
|
6 |
2016 |
6
🐜
|
|
🐜
|
Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection.
12 auth.
H. Belmont,
S. Price-Schiavi,
B. Liu,
H.-i. Lee,
M. Fernandez,
R. L. Wong,
...
J. Builes,
P. Rhode,
X. Zhu,
H. C. Wong,
C. Bigbee,
J. Flynn
|
6 |
2006 |
6
🐜
|
